Company's Prostate Cancer Vaccine Close To Moving Forward
BATON ROUGE (AP) — Officials at a Baton Rouge-based pharmaceuticals company believe the firm is close to commercializing a vaccine for prostate cancer.
The New Orleans Advocate’s Ted Griggs reports an FDA-approved Phase 1 trial of the ProscaVax vaccine, developed by OncBioMune Pharmaceuticals Inc., is nearing completion at the University of California-San Diego to make sure the vaccine is safe for people.
Next year, Harvard Health System will perform a Phase 2 trial, which will show whether the vaccine is effective.
OncBioMune CEO Jonathan Head says if the vaccine is licensed, the company will be able to fund the research for other cancers that now lack good therapies.
According to the American Cancer Society, in 2015, an estimated 220,800 new cases of prostate cancer will be diagnosed in the United States.
